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Background: The relative contribution of COX-2 and COX-1 to prostanoid formation under neuroinflammation is
complex.
Results: LPS inducedCOX-2 andmPGES1 but down-regulatedCOX-1 andTS in astroglia. These effects accounted for the high
production of PGE2.
Conclusion: PGE2 after LPS results from the coordinated COX-2 up-regulation and COX-1 down-regulation in astrocytes.
Significance: Changes in COX-2 and COX-1 expression mediate astroglial PGE2 generation in neuroinflammation.
Pathological conditions and pro-inflammatory stimuli in the
brain induce cyclooxygenase-2 (COX-2), a key enzyme in
arachidonic acidmetabolismmediating the production of pros-
tanoids that, among other actions, have strong vasoactive prop-
erties. Although low basal cerebral COX-2 expression has been
reported, COX-2 is strongly induced by pro-inflammatory chal-
lenges, whereas COX-1 is constitutively expressed. However,
the contribution of these enzymes in prostanoid formation var-
ies depending on the stimuli and cell type. Astrocyte feet sur-
round cerebralmicrovessels and releasemolecules that can trig-
ger vascular responses. Here, we investigate the regulation of
COX-2 induction and its role in prostanoid generation after a
pro-inflammatory challenge with the bacterial lipopolysaccha-
ride (LPS) in astroglia. Intracerebral administration of LPS in
rodents induced strong COX-2 expression mainly in astroglia
and microglia, whereas COX-1 expression was predominant in
microglia and did not increase. In cultured astrocytes, LPS
strongly induced COX-2 and microsomal prostaglandin-E2
(PGE2) synthase-1, mediated by the MyD88-dependent NFB
pathway and influenced by mitogen-activated protein kinase
pathways. Studies in COX-deficient cells and using COX inhib-
itors demonstrated that COX-2 mediated the high production
of PGE2 and, to a lesser extent, other prostanoids after LPS. In
contrast, LPS down-regulated COX-1 in an MyD88-dependent
fashion, andCOX-1 deficiency increased PGE2 production after
LPS. The results show that astrocytes respond to LPS by a COX-
2-dependent production of prostanoids, mainly vasoactive
PGE2, and suggest that the coordinated down-regulation of
COX-1 facilitates PGE2 production after TLR-4 activation.
These effects might induce cerebral blood flow responses to
brain inflammation.
Cyclooxygenases (COX),3 also known as prostaglandin G/H
synthases, play a crucial role in inflammation and are targets of
widely used nonsteroidal anti-inflammatory drugs. There are
two main COX enzymes, COX-1 and COX-2, that participate
in the metabolism of arachidonic acid generating the unstable
product prostaglandin (PG) G2 that is reduced to PGH2. PGH2
is the substrate of prostaglandin isomerases that give rise to a
family of vasoactive compounds called prostanoids, including
molecules such as prostaglandins, thromboxane, and prostacy-
clin. There is cellular specificity for the production of certain
prostanoids, and they exert different actions depending on the
type of molecule produced and on the specific receptors that
become activated (1). Although COX-1 is constitutively
expressed in most tissues, COX-2 is an inducible enzyme that
responds to pro-inflammatory stimuli.
COX-2 is induced in brain cells under pathological condi-
tions, but the role of the COX isoforms in brain diseases is not
clearly established. Cox-2-deficient mice are protected against
brain ischemia (2), and inhibition of COX-2 provides beneficial
effects against ischemic damage and neuronal death (3–6), sug-
gesting a detrimental effect of COX-2 in stroke. In contrast, in
neurodegenerative diseases, COX-2 inhibitors are not protec-
tive inmousemodels of Alzheimer disease (7) and did not show
benefits in clinical trials in Alzheimer disease patients (8) or in
patients with mild cognitive impairment (9). Furthermore,
COX-2 inhibitors increase the risk of cardiovascular and cere-
brovascular pathology (10), and Cox-2-deficient mice show
exacerbated brain inflammation, leukocyte infiltration, and
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blood-brain barrier damage after exposure to the bacterial
lipopolysaccharide (LPS) (11–15), suggesting some beneficial
action of COX-2 in inflammation. Furthermore, COX-2 might
contribute to neurovascular coupling because COX-2 inhibi-
tors abrogate the increases in cerebral blood flow (CBF)
induced by neuronal activation in rats (16). Exposure to LPS has
been reported to induce vasodilation (17) and increaseCBF (18)
through a mechanism involving inducible NOS and the NOX2
subunit of the superoxide-producing enzymeNADPH oxidase.
Because LPS induces strong expression of COX-2 in the brain,
it is feasible that vasoactive COX-2 products might also be
involved in CBF regulation.
In this study we examined the effect of intracerebral admin-
istration of LPS on the cellular expression of COX-2 and found
strong up-regulation in microglia and astrocytes. Because
astrocytes are recognized as important players in CBF regula-
tion under physiological and pathological conditions (19), we
then investigated the prostanoids induced by LPS and the COX
isoforms involved in prostanoid generation in purified astro-
cyte cultures. The results show that the LPS challenge strongly
induced COX-2 in astrocytes through a MyD88/NFB-depen-
dent mechanism, show the crucial role of COX-2 in prostanoid
production after LPS, and show that PGE2 is the major product
of arachidonic acid metabolism under these experimental con-
ditions. Furthermore, we found that LPS down-regulatesCox-1
gene expression and that Cox-1-deficient cells produce more
PGE2 than the WT, indicating some negative effect of COX-1
on the COX-2-dependent production of PGE2 in astrocytes
after LPS.
EXPERIMENTAL PROCEDURES
Animals—Animal work was authorized by the Ethical Com-
mittee of the University of Barcelona, and it was performed in
agreement with the local regulations and in compliance with
the Directives of the European Community. Four-month-old
male Sprague-Dawley rats were obtained from Charles River
(Lyon, France). MyD88 knock-out (KO) mice in a C57Bl/6
background were obtained from Oriental Bioservices, Inc.
(Kyoto, Japan). MyD88 KOmice (/) were crossed with wild
type (WT) (/) C57Bl/6mice (Charles River), and a colony of
MyD88 heterozygousmice (/) was kept in the animal house
of the University of Barcelona School of Medicine. Each indi-
vidual animal born from the heterozygous progenitors was
genotyped, and the MyD88 KO and the MyD88 WT animals
were selected for the studies described below. COX-1 and
COX-2 heterozygous mice were from Taconics Inc. (Hudson,
NY). COX-2 or COX-1 heterozygous females (/) were
crossed with homozygous (/) males; all had a mixed
B6;129P2 background. We genotyped each animal of the off-
spring, and the KO animals were selected for the studies,
although the correspondingWT animals were used as controls.
Genotyping Protocols—Genotyping was carried out by doing
PCR on DNA extracted from tail biopsies. The Extract-N-Amp
Tissue PCR kit (Sigma) was used for the extraction of DNA and
preparation of PCRs according to the manufacturer’s instruc-
tions. For experiments with COX KO or WT cells, the
following sets of primers (20) were used for PCR: Cox-1 KO
forward, 5-GCAGCCTCTGTTCCACATACAC-3; Cox-1
WT forward, 5-AGGAGATGGCTGCTGAGTTGG-3;
Cox-1 reverse (common), 5-AATCTGACTTTCTGAGTT-
GCC-3; Cox-2 KO forward, 5-ACGCGTCACCTTA-
ATATGCG-3; Cox-2 WT forward, 5-ACACCTTCAA-
CATTGAAGACC-3; Cox-2 reverse (common), 5-ATC-
CCTTCACTAAATGCCCTC-3. Amplicon sizes were as
follow: Cox-1 WT, 601 bp; Cox-1 KO, 646 bp; Cox-2 WT,
725 bp; Cox-2 KO, 905 bp. The cycling parameters were
94 °C, 5 min for initial denaturation, followed by 34 cycles of
denaturation at 94 °C for 30 s, primer annealing at 60 °C
(Cox-1) or 57 °C (Cox-2) for 30 s, and extension at 72 °C for
1 min. The last cycle was followed by an additional extension
step at 72 °C for 5 min. The supplemental material depicts an
example of a genotyping reaction (supplemental Fig. 1). For
experiments with MyD88 KO mice, the genotyping proce-
dure has been reported previously (21).
LPS Administration to Rodents—Rats and mice were anes-
thetized with isofluorane and placed in a stereotaxic apparatus
for injection of LPS or the vehicle (phosphate-buffered saline
(PBS)) in the right striatum. For rats, LPS (5 l of 1 g/ml) or
the same volume of vehicle was injected at the following coor-
dinates according to the atlas of Paxinos and Watson (22) in
relation to Bregma as follows: 0.5 mm antero-posterior, 3 mm
lateral, and 5 mm ventral. For mice, LPS (0.7 l of 1 g/ml) or
vehicle was injected at the following coordinates: 0.5 mm
antero-posterior, 2 mm lateral, and 3 mm ventral. After 8 h,
animals were anesthetized with isofluorane and perfused
through the heart with saline to remove blood from the brain
vessels, and brain tissue was obtained after dissection of the
ipsilateral and contralateral striatum and was immediately fro-
zen and kept at 80 °C until further use. A different set of
animals was processed for immunohistochemistry.
Cell Cultures—Glial cell cultures enriched in astrocytes were
prepared from the cerebral cortex of 1–2-day-old rats or mice
as described previously (21, 23), with minor modifications. In
brief, cellsweremaintained at 37 °C in a humidified atmosphere
of 5% CO2, 95% air in culture medium (DMEM (Invitrogen) for
rat astrocytes, and DMEM/F-12 nutrient (1:1) (Invitrogen) for
mouse astrocytes). Media were supplemented with 10% fetal
bovine serum (FBS; Invitrogen) and 4 ml/liter of a mixture of
penicillin/streptomycin 10,000 units, 10,000 g/ml (Invitro-
gen). Cells were subcultured to obtain purified astroglia cul-
tures, as follows. At confluence after 8–10 days in vitro, cells
were treated with 4 M antimitotic cytosine arabinoside
(Sigma) for 5 days to eliminate dividing cells, i.e.mostly micro-
glia and progenitors. Flasks were shaken overnight, and the
remaining astrocyte adherent monolayer was detached with
trypsin 0.0125%, 0.2 mM EDTA and seeded at 10  104 cells/ml
with incubation medium (as above). Purified astrocytes were
treatedwhen cells reached confluence at 4 days after subcultur-
ing. FBS was reduced to 1% 16 h prior to treatments.
Rat astrocyte cultures contained only 2.01  1.68% of con-
taminating microglia cells, as reported (21). Purified mouse
astrocyte cultures also contained very little microglia, as esti-
mated by immunofluorescence and by examining the expres-
sion ofCD11bmRNA (see below for description of thesemeth-
ods). After immunofluorescence with an antibody against a
microglialmarker (Iba-1) and an antibody against glial fibrillary
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acidic protein (GFAP) to label astrocytes (supplemental Fig. 2),
we counted (n  24 fields for two cultures, using 20 magnifi-
cation) the percentage of Iba-1 immunoreactive cells and esti-
mated that the % of contaminating microglia in the astrocyte
cultures was 0.77  0.49%. Independently, we calculated the
percentage of CD11b expression per culture by real time RT-
PCR as a marker of microglia and used purified microglia cul-
tures (obtained as reported previously (24)) as a reference for
100% CD11b expression. According to this procedure, CD11b
expression (mean S.D.,n 5) in astroglia cultureswas 1.41
1.22%, supporting that contaminating microglia cells were very
scarce in the purified astroglia cultures.
For experiments withMyD88 KO, Cox-1 KO, and Cox-2 KO
cells, individual astrocyte cultures were obtained from each
newborn animal and, after genotyping, the/ (KO) and/
(WT) cultures were selected for use in further experiments.
Experiments in KO andWT cells were carried out in parallel.
Drug Treatments—Cells were exposed to 10 ng/ml LPS
(Escherichia coli 055:B5) (Sigma) for times ranging from 4 to
24 h. Cells were treated with the following mitogen-activated
protein kinase (MAPK) inhibitors (Calbiochem):MAPK kinase
(MEK) inhibitors 1,4-diamino-2,3-dicyano-1,4-bis(2-amino-
phenylthio)butadiene (U0126) (1–25 M) and PD98059 (1–40
M); p38 MAPK inhibitor trans-4-[4-(4-fluorophenyl)-5-(2-
methoxy-4-pyrimidinyl)-1H-imidazol-1-yl]cyclohexanol
(SB239063) (0.1–25M); and stress-activated SAPK/MAPK in-
hibitor anthra(1,9-cd)pyrazol-6(2H)-one (SP600125) (1–25
M) that was dissolved in dimethyl sulfoxide (DMSO) (Sigma)
and given 30min prior to LPS. COX-2 inhibitorN-[cyclohexy-
loxy-4-nitrophenyl] methanesulfonamide (NS-398) was pur-
chased from Tocris Bioscience (Ellisville, MO), dissolved in
saline, pH 13, and used at 3 M. COX-1 inhibitor 5-(4-
chlorophenyl)-1-(4-methoxyphenyl)-3-trifluoromethyl-
pyrazole (SC-560) was purchased from Calbiochem, dis-
solved in DMSO, and used at 10 nM. Treatment with COX
inhibitors was carried within 30–60 min prior to LPS. The
cytosolic phospholipase A2 (cPLA2) inhibitor arachidonyl-
trifluoromethyl ketone (Calbiochem) was dissolved in
DMSO and used at 2 M 30min before LPS. For all drugs, the
corresponding vehicle was used to check for any nonspecific
effects in all the experiments. The final concentrations of the
vehicles, DMSO or saline, pH 13, did not exceed 0.25 and
0.3%, respectively. No effects of the vehicles on the parame-
ters studied were detected.
siRNA Transfection—Twenty four hours after subculturing,
rat astrocytes were transfected with specific siRNA sequences
TARGETplusTM SMARTpool siRNA from Thermo Fisher Sci-
entific Dharmacon Products (Lafayette, CO). TARGETplusTM
SMARTpool siRNAdirected against NFB p65 (L-0800033-01,
Rat RelA, NM_199267), NADPH oxidase flavocytochrome
b558 gp91(phox) (J-093524), COX-1 (19224, PTGS1), and
against themouseMAPKsMAPK1 (26413, Erk2,NM_011949),
MAPK10 (26414, JNK3, NM_009158), and MAPK14 (24416,
p38, NM_011951). ON-TARGETplus nontargeting siRNA
(D-001810-01) was used as a negative control (nonsilencing).
These siRNAs were predesigned by the maker to minimize off-
side effects (23), and they were used at 100 nM and transfected
with OligofectamineTM (Invitrogen), as described previously
(23). Astrocytes were used 4 days after siRNA transfection. The
silencing effect was verified by RT-PCR and/or Western
blotting.
Western Blotting—Astrocytes were lysed in buffer containing
protease inhibitors. Twentyg of protein extract were resolved
by SDS-PAGE, and proteins were transferred to a polyvi-
nylidene difluoride membrane. Rabbit polyclonal antibodies
were used against the following: COX-2 (160126, Cayman
Chemical) diluted 1:500; thromboxane synthase (TS) (ab39362,
Abcam, Cambridge, UK) diluted 1:1,000; microsomal prosta-
glandin E synthase-1, PGES-1 (AS03 031, Agrisera, Vännas,
Sweden) diluted 1:1,000; c-Jun NH2-terminal kinase (JNK)
(J4500, Sigma), and p38 MAPK (M0800, Sigma) both diluted
1:10,000. A goat polyclonal antibody against COX-1 (Santa
Cruz Biotechnology, Santa Cruz, CA) was used diluted 1:1,000.
Mouse monoclonal antibodies were used against ERK1/2
(610123, BD Biosciences) diluted 1:50,000 and against -tubu-
lin (T4026, Sigma) diluted 1:50,000, which was used as control
for protein gel loading. Antibodies were diluted in Tris-buff-
ered saline containing 0.5%Tween 20 andwere incubated over-
night at 4 °C. On the following day, the membranes were incu-
batedwith horseradish peroxidase-conjugated goat anti-mouse
IgG (Bio-Rad) diluted 1:1,000 or goat anti-rabbit IgG (Amer-
sham Biosciences) 1:2,000 for 2 h at room temperature. The
blots were developed with the use of a chemiluminescent sub-
strate (ECL Western blotting Analysis System; Amersham
Biosciences).
Immunocytochemistry—Astrocytes were seeded on polyly-
sine-coated coverslips. Cells were washed in PBS and fixed in
4% paraformaldehyde for 30 min. Cells were permeabilized
with 0.2%TritonX-100 (Sigma) in PBS for 10min, blockedwith
10% goat or horse serum in PBS for 1 h, and incubated over-
night at 4 °C with one of the following primary antibodies: a
rabbit polyclonal antibody against Iba-1 (019-19741, Wako
ChemicalsGmbH,Neuss, Germany) diluted 1:1,000 or amono-
clonal antibody against GFAP (G3893, Sigma) diluted 1,1000.
The next day, cells were washed and incubated with green
fluorescence Alexa Fluor 488 dye-labeled goat anti-rabbit IgG
antibody and Alexa Fluor 546 goat anti-mouse IgG diluted
1,1000 (Molecular Probes) for 1 h at room temperature. There-
after, astrocytes were stained with Hoechst to visualize the
nuclei. The coverslips were mounted onto microscope slides
usingMowiolmountingmedium (Calbiochem,Merck). Obser-
vations were performed with an Olympus IX70 fluorescence
microscope.
For immunohistochemistry in brain tissue, animals were
perfused through the heart with saline followed by paraformal-
dehyde ( 4%) in phosphate buffer, pH 7.4. The brain was
removed, post-fixed with paraformaldehyde overnight, and
then kept in phosphate buffer before slicing it in a vibratome to
obtain 30-m-thick coronal sections. Brain sections were cryo-
protected in a solution containing glycerol andwere kept frozen
at20 °C. Immunohistochemistry was performed free-floating
with vibratome sections, as reported previously (25). Endoge-
nous peroxidases were blocked with 3% hydrogen peroxide and
10% methanol in PBS for 25 min. Sections were incubated for
2 h in 3% normal horse or goat serum for mousemonoclonal or
rabbit polyclonal antibodies, respectively, to block unspecific
Cox-2 Induction and Cox-1 Down-regulation by LPS
6456 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 287 • NUMBER 9 • FEBRUARY 24, 2012
binding sites, washed in T-PBS (PBS containing 0.5% Triton
X-100), and incubated overnight at 4 °C with either mouse
monoclonal antibody against COX-1 (160110, Cayman Chem-
ical) diluted 1:100, or rabbit polyclonal anti-COX-2 antibody
(160126, Cayman Chemical) diluted 1:500. Thereafter, the sec-
tions were rinsed in T-PBS and incubated for 1 h with a bioti-
nylated secondary antibody (1:200, Vector Laboratories), fol-
lowed by incubationwith 1% avidin-biotin-peroxidase complex
(ABC kit, Vector Laboratories). The reaction was visualized
with 0.05% diaminobenzidine in 0.03% hydrogen peroxide in
PBS. Double immunohistochemistry was carried out following
the first immunoreaction with COX-1 or COX-2. The second
primary antibodies used were as follows: a rabbit polyclonal
antibody against GFAP (Z0334, DakoCytomation) diluted
1:500, which labels astroglia, or a rabbit polyclonal antibody
against Iba-1 (as above) diluted 1:500 to detect microglia. Sec-
tions were then incubated with the avidin-biotin complex,
washed with 0.01 M sodium phosphate buffer, pH 6, and prein-
cubated for 10 min with 0.01% benzidine dihydrochloride and
0.025% sodium nitroferricyanide in 0.01 M sodium phosphate
buffer, pH 6. The reaction was developed with this solution
containing 0.005% H2O2. Immunoreaction controls included
omission of the first or second primary antibodies. The induc-
tion of COX-2 in microglia and in astrocytes was assessed by
counting the number of GFAP and of Iba-1 cells expressing
COX-2 in the ipsilateral striatum. Microscopic photographs
(20 objective) of three areas surrounding the injection site
were taken per brain section in three brain sections per animal.
The proportion of microglia (Iba-1) and of astroglia (GFAP)
expressing COX-2 was calculated in each photograph, and the
average value of all the photographs per animal was calculated.
Values are expressed as the mean of four animals treated with
LPS and three animals treated with PBS.
Real Time RT-PCR—Total RNA was extracted using the
PureLink RNA kit (Invitrogen). RNA quantity and purity were
determined using ND-1000 microspectrophotometer (Nano-
Drop Technologies, Wilmington, DE). One g of total RNA
was reverse-transcribed using a mixture of random primers
(HighCapacity cDNAreverse transcription kit, AppliedBiosys-
tems). Real time quantitative RT-PCR analysis was carried out
by SYBR Green I dye detection (11761500, Invitrogen) using
the iCycler iQTM Multicolor real time detection system (Bio-
Rad). PCR primers were designed with the aid of Primer3 soft-
ware to bridge the exon-intron boundaries within the gene of
interest to exclude amplification of contaminating genomic
DNA. Several genes were assayed as loading controls (Hprt1,
Sdha, Ywhaz, and Rpl14). Rpl14 was the control gene showing
the best stability after LPS treatment and was chosen for nor-
malization. Primers (see list in Table 1) were purchased from
IDT (Conda, Spain). Optimized thermal cycling conditions
were as follows: 1 min at 50 °C, 8 min, and 30 s at 95 °C and 40
cycles of 15 s at 95 °C and 30 s at 60 °C in which an optical
acquirement were performed. Data were collected after each
cycle and were graphically displayed (iCycler iQTM real time
detection system software, version 3.1, Bio-Rad). Melt curves
were performed upon completion of the cycles to ensure
absence of nonspecific products.Quantificationwas performed
by normalizing cycle threshold (Ct) values with the Rpl14 con-
trol gene Ct, and analysis was carried out with the 2CT
method (26).
ELISAs—The cellular supernatant was used in ELISAs to
measure the concentration of: prostaglandin E2 (PGE2, 900-
001), thromboxane B2 (TxB2, 900-002), and 6-keto-prostaglan-
din F1 (PG F1, 900-004) (Assay Designs, Ann Arbor, MI).
Statistical Analyses—One-way analysis of variance was used
for comparisons betweenmultiple groups, after testing for nor-
mality, followed by the post hoc Bonferroni test. Comparison
between two groups was carried out with the t test after verify-
ing normal distribution; otherwise, the nonparametric Mann
Whitney test was used. Linear or nonlinear regression analyses
TABLE 1
List of primer sequences for mouse and rat PCR
F means forward, and R means reverse.
Primer sequence 533 Accession no. Amplicon length Region
bp
Mouse
TNF- F, GGGGCCACCACGCTCTTCTGTC NM_013693 155 Exon 1
R, TGGGCTACGGGCTTGTCACTCG Exon 3
Cox-2 F, CCACTTCAAGGGAGTCTGGA NM_011198.3 187 Exon 3
R, AGTCATCTGCTACGGGAGGA Exon 4
Cox-1 F, GTGCTGGGGCAGTGCTGGAG NM_008969.3 281 Exon 1
R, TGGGGCCTGAGTAGCCCGTG Exon 3
mPGES-1 F, AGGCCAGATGAGGCTGCGGA NM_002415.2 195 Exon 1
R, AGCGAAGGCGTGGGTTCAGC Exon 3
PGIS F, GTGGAGGCCTCACCACGCAC NM_008968 305 Exon 5
R, CCCGGGCCTGCATCTCCTCT Exon 6
TS F, CACACGGGAGGCAGCACAGG NM_0011539.3 194 Exon 10
R, GGGCCAGCTCCAAAGGGCAG Exon 11
CD11b F, AAGCAGCTGAATGGGAGGAC NM_001082960 190 Exon 7
R, GAATGACCCCTGCTCTGTCT Exon 8
RPL14 F, GGCTTTAGTGGATGGACCCT NM_025974 143 Exon 3
R, ATTGATATCCGCCTTCTCCC Exon 4
Rat
Cox-2 F, GATTGACAGCCCACCAACTT NM_017232 149 Exon 4
R, CGGGATGAACTCTCTCCTCA Exon 5
TNF- F, GGGGCCACCACGCTCTTCTGTC NM_012675.3 155 Exon 1
R, TGGGCTACGGGCTTGTCACTCG Exon 3
RPL14 F, TCTTTGCCTATGTCAGAGGA NM_022949 144 Exon 3
R, GATAGGTATCTTAATTCGAGTCCC Exon 4
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were used for curve fits as appropriate using GraphPad
software.
RESULTS
Intracerebral Administration of LPS Induces Cox-2 inMicro-
glia and Astroglia—Intracerebral administration of LPS to rats
induced mRNA expression of Tnf- (Fig. 1A) in the ipsilateral
hemisphere at 8 h. LPS also increased the expression of Cox-2
mRNA (Fig. 1B) and COX-2 protein (Fig. 1, C and D). LPS
induces TLR-4 activation and recruitment of theMyD88 adap-
tor protein that mediates activation of the transcription factor
NFB and induction of target genes, such as the pro-inflamma-
tory cytokine TNF- (21). In agreement with this, MyD88 KO
mice did not show induction of Tnf- (Fig. 1E) or Cox-2 (Fig.
1F) mRNA in the ipsilateral hemisphere after LPS, indicating
that induction of both genes was MyD88-dependent.
LPS up-regulated the expression of Iba-1mRNA in the ipsi-
lateral hemisphere at 8 h suggesting microglial activation,
whereas expression of Gfap mRNA was not modified at this
time point (supplemental Fig. 3). However, by immunohisto-
chemistry (Fig. 2), we detected a strong induction of COX-2,
not only in microglia (Fig. 2,A–D) but also in astrocytes (Fig. 2,
E–G) of the ipsilateral hemisphere 8 h after LPS. Quantification
of the immunohistochemistry showed increased numbers of
COX-2 immunoreactive microglia (Iba-1) and astrocytes
(GFAP) after LPS (Fig. 2, P andQ). COX-1was expressed under
basal conditions preferentially in microglia (Fig. 2, H–K) and,
with a lower intensity, in astroglia (Fig. 3, L–O), and it was not
up-regulated by LPS (Fig. 2, H–O).
We then undertook an in vitro study in purified cultures of
astroglia treated with LPS to unravel the mechanisms underly-
ing COX-2 induction and prostanoid release induced by TLR-4
activation, and the effects of deficiency or inhibition of either
COX-1 or COX-2.
Regulation of COX-2 Expression in Astrocytes Challenged
with LPS—LPS induced Tnf- (Fig. 3A) and Cox-2 (Fig. 3B)
mRNA and protein expression (Fig. 3, C and D) in cultured
astrocytes, as it did in vivo (Fig. 1, A–D). The transcription
factor NFB was involved in COX-2 induction because silenc-
ing the p65 subunit of NFB with siRNA attenuated Cox-2
mRNA induction (Fig. 3E). However, this effect was not
observed by silencing other genes, such as the gp91 subunit of
FIGURE 1. LPS administration to the rat brain induced COX-2 in glial cells. Rats received an intrastriatal injection of LPS (5 l, 1 g/l) or the vehicle (PBS),
and the brain tissue was obtained 8 h later to study mRNA and protein expression. A and B, rats injected with LPS show a very pronounced increase in the
expression of Tnf- and Cox-2 mRNA in the ipsilateral hemisphere compared with that in animals receiving the vehicle or in the contralateral hemisphere (n 
3–5 rats per group). C, COX-2 protein was detected by Western blotting in the ipsilateral hemisphere 8 h after LPS. D, semi-quantification of COX-2 band
intensity indicated a significant increase of COX-2 expression after LPS (n  3 rats per group). E and F, expression of Tnf- and Cox-2 mRNA in the ipsilateral
hemisphere of mice 8 h after striatal injection of LPS (0.7 l, 1 g/l) is powerfully attenuated in MyD88-deficient mice (MyD88 KO) compared with the WT (n 
3– 4 per group). Control animals received intrastriatal injection of the vehicle (PBS). One symbol, p  0.05; two symbols, p  0.01; three symbols, p  0.001.
Symbols indicate comparison versus either (*) control or (&) LPS WT.
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NADPH oxidase complex (Fig. 3E) that was reported to medi-
ate COX-2 induction after LPS in microglia (27). The involve-
ment of NFB in mediating the induction of COX-2 after LPS
was further substantiated by the use of the inhibitor PDTC,
which attenuated the effect of LPS (Fig. 3F). We then used
astrocytes frommice deficient inMyD88 or correspondingWT
mice to explore whether COX-2 induction was dependent on
the MyD88 pathway in these cells, as observed previously in
vivo (Fig. 1, E and F). LPS failed to induce Tnf- mRNA in
MyD88-deficient astrocytes (Fig. 3G), which did not express
Cox-2 mRNA (Fig. 3H) or protein (Fig. 3I). Therefore, COX-2
induction after LPS is dependent on MyD88 and NFB.
MAPKs participate in LPS signaling (28) and can mediate
COX-2 induction (29). We used specific inhibitors of MAPK
pathways to unravel their contribution inCOX-2 up-regulation
after LPS in astrocytes. Cox-2 mRNA induction was severely
reduced by the p38 inhibitor SB23906 and by the JNK inhibitor
SP600125 but not by the MEK inhibitor U0126 (Fig. 4A). Like-
wise, COX-2 protein expression 8 h after LPSwas very sensitive
to SB239063 (from 1 M) (Fig. 4B) and SP600125 (from 10 M)
(Fig. 4C), whereas U0126 (1–25 M) had a negligible effect (Fig.
4D). This finding was validated with another MEK inhibitor,
PD98059 (from 10 to 40 M) (Fig. 4D). The same result was
found at 4 h (Fig. 4E). In agreement with this, the production of
FIGURE 2. COX-2 is induced in astrocytes and microglia after LPS in the rat brain. Immunohistochemistry against COX-2 (brown in A–G) and COX-1 (brown
in H–O) in control rat brain (A, C, E, H, J, L, and N) and after LPS (B, D, F, G, I, K, M, and O) shows co-localization of COX-2 with markers of microglia (Iba-1) (B and
D) and astroglia (GFAP) (arrow in F and G) (dark blue/purple), whereas COX-1 is predominantly expressed in microglia (H–J) and to a lower extent in astroglia
(L–N), and it is not up-regulated after LPS (I, K, M, and O). The areas indicated with rectangles in L and M are magnified in N and O, respectively. Bar scale, 30 m
(A–G, J–K, N, and O); 60 m (L and M); 120 m (H and I). P and Q, quantification of the proportion of microglia and astroglia cells expressing COX-2. Values are
expressed as % of total Iba-1 microglia (P) or GFAP astroglia (Q). n  4 –5 LPS-treated mice and n  3 mice injected with PBS. Controls are taken as the
contralateral nonaffected hemispheres, n  7. One-way analysis of variance, and *** indicates p  0.001.
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PGE2, as assessed by ELISA 8 h after LPS, was reduced by p38
and JNK inhibitors but not after MEK inhibition (Fig. 4F).
We then silenced the expression of MAPK1 (ERK2),
MAPK10 (JNK3), and MAPK14 (p38) using siRNA. Western
blotting (Fig. 4G) showed that siRNAs reduced the correspond-
ing protein expression by 65–70%. Silencing p38 and JNK3
attenuated the expression of Cox-2 mRNA and protein, but no
significant effects were observed after silencingMAPK1 (Fig. 4,
H–J). Therefore, we can conclude that induction of COX-2
expression after LPS is strongly dependent on theMyD88 path-
way NFB and on p38 and JNK pathways.
Regulation of COX-1 Expression after LPS—We also exam-
ined whether the expression of constitutive COX-1 was
affected by LPS. The expression of Cox-1 mRNA was signifi-
cantly reduced 8 h after LPS in WT astrocytes, and the same
effect was observed in Cox-2 KO cells (Fig. 5A), which we
verified did not express Cox-2 mRNA (Fig. 5B) or protein
(Fig. 5, C and D). Although the reduction of Cox-1mRNA by
LPS was already seen at 4 h (Fig. 5, G and I), COX-1 protein
expression was unaltered at this time point, but a slight
reduction was seen at 8 and 24 h (Fig. 5, E and F). The delay
in the reduction of the amount of COX-1 protein after the
decreased expression of Cox-1 mRNA might be due to the
presence of the constitutive protein that needs to follow its
turnover before reductions in mRNA can be translated into
protein decreases.
LPS-induced reduction of COX-1 was not prevented by
MAPK inhibition (Fig. 5, G and H) or by silencing MAPK
expression with siRNA (Fig. 5, I and J). However, LPS-induced
down-regulation of Cox-1 mRNA was dependent on the
MyD88 pathway because LPS did not reduce it in MyD88 KO
mice (Fig. 5K). To better substantiate this finding, we examined
whether down-regulation of COX-1 also occurred in vivo in the
mouse brain after intracerebral LPS administration. Expression
of Cox-1mRNA was significantly reduced 8 h after injection of
LPS but not after injection of PBS (Fig. 5L). This effect was
strongly attenuated in MyD88-deficient mice (Fig. 5L), sup-
porting that it was MyD88-dependent. PDTC attenuated the
reduction of Cox-1 mRNA induced by LPS in cultured cells,
suggesting that NFB was involved (Fig. 5M).
Because COX-1 and COX-2 expression responded in an
opposite way to the LPS challenge, we examined whether Cox-
FIGURE 3. COX-2 induction after LPS is dependent on NFB and MyD88 pathways. LPS (10 ng/ml) was added to rat (A, B, and E) or mouse (C–D and F–I)
astrocyte cultures, and mRNA/proteins were studied at different time points (A–D) or at 4 h. A and B, time course expression of Tnf- and Cox-2 mRNA after LPS.
C, time course of COX-2 protein expression after LPS was assessed by Western blotting. D, semi-quantification of COX-2 band intensity in C. Data were fit to the
curve with nonlinear regression analysis (one-phase exponential association). The goodness of the fit was assessed by r2. E, cells were transfected with
Oligofectamine carrying small interference RNA (siRNA) against either the p65 subunit of NFB (si-p65) or the gp91 subunit of NADPH (si-gp91). A nonsilencing
(ns) scramble double-stranded RNA was used as control. In these cells, the induction of Cox-2 mRNA is dependent on NFB. F, NFB inhibitor PDTC also prevents
Cox-2 mRNA and protein induction after LPS. G–I, induction of Tnf- (G) and COX-2 (H) mRNA is strongly reduced in astrocytes deficient in MyD88 (MyD88/)
versus the wild type (MyD88/). Likewise, COX-2 protein is detected by Western blotting in WT cells but not in MyD88-deficient cells (I). -Tubulin is shown in
the Western blots as a loading control. Values are expressed as the mean  S.E. of n  3 per condition. One symbol, p  0.05; two symbols, p  0.01; three symbols,
p  0.001. Symbols indicate comparison versus either (*) control or (&) LPS (WT or treatment control).
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1-deficient mice (Fig. 5N) showed up-regulation of Cox-2
mRNA (Fig. 5O) and protein (Fig. 4O) after LPS, which they did.
These results support that although LPS strongly induces
COX-2, it represses the expression of COX-1, and both
responses are dependent on the MyD88 pathway, whereas p38
and JNKMAPKare involved in up-regulatingCOX-2 but not in
down-regulating COX-1.
LPS Modifies the Expression of Prostaglandin Isomerases—
The types of prostanoids that are produced after COX activa-
tion depend on the action of specific prostanoid isomerases, i.e.
the enzymes responsible for the production of prostanoids
fromCOX-derived PGH2. LPS induced strong mRNA expres-
sion of one of the isoforms of PGE2 synthase, the microsomal
PGE synthase-1 (mPges-1) (Fig. 6A), in WT and Cox-1- or
Cox-2-deficient cells. Like for COX-2, induction of
mPGES-1 after LPS was dependent on the MyD88 pathway
because MyD88-deficient cells showed no increase of
mPges-1 mRNA expression (Fig. 6B). These findings show
that LPS up-regulates the expression ofmPges-1 through the
MyD88 pathway, in a manner coordinated with the induc-
FIGURE 4. LPS-induced COX-2 is dependent on p38 and JNK MAPK. LPS (10 ng/ml) was added to mouse astrocyte cultures, and mRNA/proteins were studied
at 4 or 8 h. A, astrocytes were treated with LPS in the presence or absence () of the indicated doses of MAPK inhibitors (or the vehicle): SB239063 (SB), SP600125
(SP), and U0126 (U), which inhibit the p38, JNK, and MEK pathways, respectively, and Cox-2 mRNA was studied 4 h after LPS. The results show the involvement
of p38 and JNK in LPS-induced Cox-2 mRNA. B–D, COX-2 protein expression 8 h after LPS was inhibited by SB239063 (from 1 to 25 M) (B), and SP600125 (from
10 to 25 M) (C), but not by MEK inhibitors (up to 25 M U0126 and up to 40 M PD98059) (D). E, COX-2 protein 4 h after LPS was also inhibited by p38 and JNK
inhibitors but not after MEK inhibition (U0126). F, accordingly, SB239063 and SP600125, but not U0126, inhibit the production of PGE2, as assessed by ELISA in
the culture medium 8 h after LPS. G, silencing MAPK with siRNA effectively reduces the expression of the corresponding target proteins by 65–70%. H–J,
silencing MAPK10 (JNK3) or MAPK14 (p38), but not MAPK1 (ERK2), reduces Cox-2 mRNA (H) and protein (I and J) versus treatment with nonsilencing (ns) RNA 4 h
after LPS. -Tubulin is shown in the Western blots as a loading control. Values are expressed as the mean  S.E. of n  3 per condition in at least three
independent experiments. One symbol, p  0.05; two symbols, p  0.01; three symbols, p  0.001.
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tion of COX-2, to strongly generate PGE2. In contrast to the
above findings, LPS down-regulated the expression of pros-
tacyclin synthase (Pgis) mRNA (Fig. 6C) and, to a greater
extent, thromboxane synthase (Ts) mRNA (Fig. 6D).
Accordingly, although after LPS the expression of mPGES-1
protein significantly increased (Fig. 6E), the expression of TS
protein tended to be progressively lower than in controls
(Fig. 6F). The latter effects on TS paralleled the down-regu-
lation of COX-1 expression after LPS (Fig. 5, A and E), sug-
gesting common regulatory pathways.
LPS Exposure Induces Prostanoid Production in Astrocytes—
COX enzymes metabolize arachidonic acid to prostaglandins
PGG2 and PGH2 that are rapidly converted by cell-specific
prostaglandin isomerases into different prostanoids, including
FIGURE 5. LPS down-regulates COX-1 expression in astrocytes. Cultured mouse astrocytes were treated with LPS (10 ng/ml) for 4, 8, or 24 h. A, Cox-1 mRNA
expression is down-regulated 8 h after LPS in WT (/) and Cox-2-deficient cells (/). B–D, lack of expression of Cox-2 mRNA and protein in Cox-2 KO cells is
shown compared with WT. E and F, COX-1 protein expression decreases from 8 h after LPS but not at 4 h. G–J, down-regulation of COX-1 after LPS is not
MAPK-dependent because it is not altered by MAPK inhibitors (G and H) or by silencing the indicated MAPK (I and J) (ns indicates treatment with control
nonsilencing RNA). K, LPS-induced down-regulation of Cox-1 is not observed in MyD88-deficient cells, suggesting that it is MyD88-dependent. L, intracerebral
administration of LPS to mice also induces a reduction of Cox-1 mRNA expression in the ipsilateral (ipsi) hemisphere 8 h after LPS, and this effect is strongly
attenuated in MyD88-deficient mice. contra, contralateral. M, NFB inhibition with PDTC (10 M) significantly attenuates the reduction of Cox-1 mRNA induced
by LPS at 4 h in cultured astrocytes. N, compared with WT cells, low levels of Cox-1 mRNA are found in Cox-1-deficient cells, and COX-1 protein is not detected
in these cells by Western blotting (inset). O, Cox-1 KO cells produce Cox-2 mRNA and protein 4 and 8 h after LPS, respectively. -Tubulin is shown as a loading
control. n  3 per condition in each result. One symbol, p  0.05; two symbols, p  0.01; three symbols, p  0.001. Symbols indicate comparison versus either (*)
control or (&) LPS (WT or untreated).
FIGURE 6. LPS induces expression of mPges-1 mRNA but not of the enzymes that synthesize other prostanoids. Astrocytes of Cox-1 or Cox-2 KO mice
(/) and their respective wild type (/) astrocytes were treated with LPS (10 ng/ml), and mRNA was extracted at 8 h. A, LPS strongly induces microsomal
PGE2 synthase-1 (mPGES1) mRNA in the different genotypes. c, control. B, induction of mPges1 mRNA after LPS is dependent on the MyD88 pathway, as shown
by lack of mPges-1 mRNA up-regulation in MyD88-deficient (MyD88/) cells after LPS. C and D, expression of prostacyclin synthase (PGIS) mRNA (C) and that
of TS mRNA (D) is reduced after LPS in all genotypes. E and F, accordingly, in astrocytes from C57 WT mice, LPS significantly up-regulates the expression of
mPGES1 protein (E), although TS protein shows a nonsignificant tendency to progressively decrease with time versus controls (F). n  3 for each genotype. One
symbol, p  0.05; two symbols, p  0.01; three symbols, p  0.001. * indicates comparison versus control; & indicates comparison versus LPS in WT.
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PGE2, PGF2, prostacyclin (PGI2), and thromboxane A2
(TxA2), among others.We examined the profile of several pros-
tanoids induced by LPS in the culture medium of rat astrocytes
by ELISAs. TxA2 has a half-life of only a few seconds (30), and
its production is typically assessed bymeasuring TxB2, which is
a stable metabolite. PGI2 has a half-life of 60min in plasma, but
it is stable for only a few minutes in buffer (30), and its produc-
tion is typically monitored by measurement of 6-keto-prosta-
glandin F1 (PGF1). LPS caused a very strong accumulation of
PGE2 in the cell culturemedium of rat astrocytes from 2 to 24 h
(Fig. 7, A and B), and to a lesser extent it increased the concen-
tration of TxB2 (Fig. 7, C and D) and of PGF1 (Fig. 7, E and F)
FIGURE 7. LPS induces secretion of prostanoids to the culture medium. Purified cultures of rat astrocytes were exposed to LPS (10 ng/ml) for different times,
and the medium was collected and studied by ELISA. ELISAs were carried out in five independent experiments, and curves from representative experiments are
shown. A, time course of PGE2 concentrations in the culture medium. B, LPS does not induce PGE2 in the presence of the Cox-2 inhibitor NS-398 (3 M), and PGE2
concentration is lower in the presence of the Cox-1 inhibitor SC-560 (10 nM). C, time course of TxB2 as an indicator of the generation of TxA2. D, NS-398 strongly
reduces the production of TxB2 induced by LPS, whereas SC-560 attenuates the effect of LPS. E, time course of PGF-1 concentration to indirectly assess the
formation of prostacyclin. F, NS-398 strongly reduces the concentration of PGF1- in the medium, whereas some reduction is observed with the Cox-1 inhibitor
(inh) SC-560. G–I, cPLA2 inhibitor arachidonyltrifluoromethyl ketone (2 M) completely abrogates LPS-induced prostanoid formation as assessed at 8 h after LPS
exposure. AA, arachidonic acid. One symbol, p  0.05; two symbols, p  0.01; three symbols, p  0.001. * indicates comparison versus control. & indicates
comparison versus LPS alone. Data (mean  S.D.) were fit to the curve with nonlinear regression analysis (one-phase exponential association) in A and C, and
with linear regression in E. The goodness of the fit was assessed by r2.
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at 8 and 24 h. The cPLA2 inhibitor arachidonyltrifluoromethyl
ketone fully prevented the production of prostanoids (Fig. 7,
G–I), suggesting the involvement of cPLA2 in arachidonic acid
mobilization after LPS.
Prostanoid Production after LPS Treatment Is Prevented by
COX-2 Inhibitors—COX-2 inhibitor NS-398 strongly blocked
LPS-induced PGE2, TxA2, and PGI2 production, whereas
COX-1 inhibition with SC-560 only partly attenuated the gen-
eration of prostanoids after LPS in rat astrocytes (Fig. 7, B, D,
and F). These results suggested that COX-2was themainmedi-
ator of prostanoid production after LPS and pointed to a small
contribution of COX-1 due to a weak inhibitory effect of
SC-560. Although SC-560 is widely used to inhibit COX-1
and specific inhibition of this enzyme has been shown in cell-
free systems, cell studies suggest that this compound may also
exert some nonspecific inhibitory effects on COX-2 (31). This
possible inhibition of COX-2might explainwhywe found some
partial inhibitory effects of SC-560 on prostanoid production in
our system. To further investigate if SC-560 has COX-1-inde-
pendent effects, we used astrocytes from COX-1-deficient
mice. SC-560 significantly (p  0.001) reduced the production
of PGE2, PGF1, and TxB2 (supplemental Fig. 4) induced by
LPS in Cox-1 KO cells, thus indicating that this compoundmay
have COX-1-independent effects.
Prostanoid Production after LPS Treatment Is Dependent on
COX-2—Weshowed above that the induction ofCOX-2byLPS
was strongly inhibited inMyD88-deficient cells (Fig. 3,H and I).
For this reason, we then examined whether LPS-induced pros-
tanoid production was abrogated in these cells. Compared with
the previous findings of prostanoid release after LPS in rat
astrocytes, we noticed that mouse astrocytes produced less
thromboxane and more prostaglandin than rat astrocytes,
although in both species PGE2 was the prostanoid more abun-
dantly generated in response to LPS. Lack ofMyD88 prevented
the production of prostanoids after LPS (Fig. 8, A–C), thus fur-
ther supporting that COX-2 was themainmediator of prostan-
oid production after this challenge. Because COX-2 was not
induced in MyD88 KO cells, the slightly higher production of
TxB2 after LPS than in controlMyD88KOcellsmight be attrib-
utable to COX-1 activity and related to the finding that the
basal COX-1 expression was not down-regulated after LPS in
MyD88 KO cells (Fig. 4I).
We then used astrocytes obtained from mice deficient in
Cox-1 or Cox-2 and their corresponding WT controls to vali-
date the above findings, excluding possible interferences
because of nonspecific effects of the drug inhibitors. Astrocytes
lackingCox-2 did not produce PGE2 (Fig. 8D), PGI2 (Fig. 8E), or
TxA2 (Fig. 8F) in response to LPS, thus confirming that COX-2
was themain enzyme involved in the production of prostanoids
induced by LPS in astrocytes. Under basal nonstimulated con-
ditions, the concentration ofTxB2was not reduced in cells lack-
ing Cox-2 compared with the WT, although they showed very
low levels of PGE2 and PGF1, suggesting that COX-1 is
involved in the low basal production of TxA2 in astrocytes. This
is in agreement with the previous observation in MyD88-defi-
cient cells, where LPS did not induce COX-2 but did not down-
regulate COX-1 either. These cells showed an increase in the
production of TxB2 after LPS (Fig. 8C) that is attributed to the
basal activity of COX-1 metabolizing the arachidonic acid
newly generated after LPS-induced cPLA2 activation.
Cox-1-deficient cells produced PGE2 after LPS to a greater
extent than the corresponding WT astrocytes (Fig. 8G), show-
ing that COX-2 is the enzyme responsible for PGE2 production
and suggesting some negative regulatory effect of COX-1 on
PGE2 production after LPS. Also, LPS increased the production
of PGI2, as assessed by measuring PGF1 (Fig. 8H), and TxA2,
as assessed bymeasuring TxB2 (Fig. 8I), inCox-1-deficient cells
suggesting the involvement of COX-2. To add further support
to these findings, we silencedCox-1with siRNA (Fig. 8J). Under
these conditions, a small but significant increase in the produc-
tion of PGE2 after LPS was observed (Fig. 8K), whereas the
production of PGI2 (Fig. 8L) and TxA2 (Fig. 8M) was not
altered. Altogether, these results show that COX-1 activity
maintains basal production of prostanoids in cultured astro-
cytes but does not have amajor role in the increased production
of prostanoids after LPS.
DISCUSSION
These results show that the production of prostanoids
induced by LPS in glial cells is essentially mediated by COX-2.
The MyD88-dependent pathway and the transcription factor
NFB were involved inCox-2 gene expression. In addition, p38
and JNK MAPK pathways influenced Cox-2 expression, thus
revealing a complex regulation of the expression of this gene in
response toTLR-4 activation in astroglia. COX-2 inductionwas
accompanied by strong production of PGE2 and, to a lesser
extent, other prostanoids. Several lines of evidence suggest that
the COX isoforms are coupled to the activity of the various
prostaglandin isomerases favoring the production of certain
prostanoids in a cell type-dependent manner (32). The strong
production of PGE2 in astrocytes after LPS is in concordance
with the enhanced expression of the microsomal isoform of
prostaglandin E synthase-1 (mPGES-1), in agreement with pre-
vious findings (33). In addition, here we report that the expres-
sion of the mPges-1 gene after LPS was up-regulated through
the MyD88 pathway, like Cox-2. Therefore, LPS induces the
coordinated expression of COX-2 and mPGES-1, which
appeared to be functionally coupled and accounts for the high
production and release of PGE2 in astrocytes, in a manner sim-
ilar to the responses described in macrophages (34).
In a previous study, induction of COX-2 and mPGES-1 was
mainly found in microglia in the substantia nigra 48 h after
intracerebral injection of LPS (35). In contrast, we also observed
the induction of COX-2 in astrocytes 8 h after LPS injection
into the striatum. Besides any regional differences in the reac-
tion to LPS, it is likely that the time course of the glial reaction
to this challenge accounts for the observed differences.
Increased expression of mPGES-1 has been reported under
pathological conditions, e.g. in the brain of Alzheimer disease
patients (36), and the enzyme is up-regulated in astrocytes
stimulated with -amyloid (37). Also, after intracerebral hem-
orrhage, strong induction of COX-2 and mPGES-1 was found
in astrocytes (38). Therefore, the findings reported here in cul-
tured cells might be relevant to certain neuropathological
conditions.
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In contrast to the increased expression of COX-2 and
mPGES-1, the expression of COX-1 was down-regulated in
astrocytes after TLR-4 activation. Reduced expression of
COX-1, together with increased COX-2 expression, was previ-
ously found in the lungs and hearts of LPS-treated rats (39). In
addition, we found that LPS down-regulated the expression of
the Ts gene in astrocytes, suggesting some link in the control of
the expression ofCox-1 andTs. Despite down-regulation ofPgis
andTsmRNA, LPS enhanced the production of PGI2 and TxA2
but to a lower extent than it increased PGE2. This apparently
contradictory effect (i.e. reduction of mRNA but increase in
enzymatic products) could be due to the time delay needed for
an effective reduction of protein content following decreases of
constitutive mRNA expression. It is feasible that down-regula-
tion of these genes limits the production of PGI2 and TxA2 in
astrocytes, while favoring the production of PGE2 because of
up-regulation of mPGES-1. Under basal nonstimulated condi-
tions, Cox-2-deficient astrocytes produced less PGI2 and TxA2
FIGURE 8. LPS-induced prostanoid production is dependent on COX-2 although COX-1 exerts selective regulatory effects. Purified cultures of mouse
astrocytes were treated with LPS (10 ng/ml), and the concentration of prostanoids in the culture medium was studied by ELISA. Cells were collected at 4 and
8 h (A–C), or 8 h (D–I) after LPS. A–C, production of prostanoids is strongly attenuated in MyD88-deficient cells. D–F, LPS does not induce PGE2 (G), PGF1 (H),
or TxB2 (I) in Cox-2 KO cells (/). G–I, production of PGE2 induced by LPS is enhanced in Cox-1-deficient astrocytes (/) (G). In contrast, the production of
PGF1 (H) and TxB2 (I), as indirect assessments of PG and TxA2, respectively, is smaller in Cox-1 KO cells (/) compared with the wild type (/), both in the
presence or absence of LPS. J–L, silencing COX-1 expression with siRNA slightly enhances the production of PGE2 (J) but does not modify the production of PGI2
(K) or TxA2 (L). n  3 in at least two independent experiments. One symbol, p  0.05; two symbols, p  0.01; three symbols, p  0.001. * indicates comparison
versus control. & indicates comparison versus LPS in WT or after treatment with nonsilencing (ns) RNA. # indicates comparison versus control KO cells.
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than the wild type cells, and COX-2-deficient astrocytes
showed unaltered concentrations of these prostanoids, sug-
gesting that COX-1 was involved in the basal production of
PGI2 andTxA2.However, after LPS, the production of PGI2 and
TxA2 increased in Cox-1-deficient cells but not in Cox-2-defi-
cient cells, demonstrating that COX-2 was mainly responsible
for their up-regulation after this challenge. Likewise, the pro-
duction of PGE2 after LPS was fully dependent on COX-2.
However, Cox-1-deficient cells produced more PGE2 after LPS
than the correspondingWTcells, suggesting thatCOX-1 exerts
some negative control on COX-2-dependent PGE2 production
after LPS.
Taken altogether, these results demonstrate the key role of
COX-2 in prostanoid production after LPS in astrocytes and
show that the production of PGE2 also depends on down-reg-
ulation of Cox-1 gene expression. Finally, these findings show
that astrocytes respond to proinflammatory triggers with a
strong generation of vasoactive PGE2 that might exert effects
on the adjacent brainmicrovasculature and contribute tomod-
ulate CBF responses to neuroinflammation.
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